<DOC>
	<DOC>NCT02026401</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Biliary Cirrhosis.</brief_summary>
	<brief_title>Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis, Biliary</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Males or females, between 18 and 75 years of age, inclusive PBC diagnosis consistent with AASLD and EASL guidelines Stable dose of UDCA Chronic liver disease of a nonPBC etiology Evidence of clinically significant hepatic decompensation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>